RxDoctor Payments Data

Maythawee Bintvihok, MD

Critical Care Medicine · Ewa Beach, HINPI 1912359910

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Olympus Corporation Of The Americas at 54.4% of the total. Reporting peaked in 2022 at $1,569 and has fallen 73.5% since, to $416 in 2025.

$2,670in general payments, 2019–2025

Across 55 payments — averaging $48.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$1K
  • Insmed, Inc.$392
  • Sanofi$221
  • GSK$195
  • Regeneron Healthcare Solutions, Inc.$122
  • Boehringer Ingelheim$94
  • plus $194 from 8 others

What the payments were for

  • Travel & lodging$1,40753%
  • Food & beverage$1,22846%
  • Education$351%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,670 in reported general payments places this provider in the 75th percentile of 31 critical care medicine providers in Hawaii.

See all critical care medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$38,972
Medicare patients
131
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$145,075
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$23,827
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,735
SymbicortBudesonide/Formoterol Fumarate28$6,265
Albuterol Sulfate HfaAlbuterol Sulfate93$2,431
Montelukast Sodium42$672
Azithromycin17$296
Prednisone15$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$195$151,810191 claims
AstraZenecaBreztri Aerosphere, Symbicort$38$30,09265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 31 critical care medicine providers in Hawaii.

Other critical care medicine in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →